Article info
Review
Paraproteinaemic neuropathy: MGUS and beyond
- Correspondence to Dr Michael P T Lunn, Centre for Neuromuscular Disease, National Hospital for Neurology and Neurosurgery, London WC1N 3BG, UK; michaellunn{at}nhs.net
Citation
Paraproteinaemic neuropathy: MGUS and beyond
Publication history
- Accepted June 27, 2021
- First published July 19, 2021.
Online issue publication
November 18, 2021
Article Versions
- Previous version (19 July 2021).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.
Other content recommended for you
- Ultrasensitive assay technology and fluid biomarkers for the evaluation of peripheral nerve disease
- Pragmatic guide to peripheral nerve disease and the role of clinical biomarkers
- Untangling a case of painful neuropathy
- AL amyloidosis presenting with isolated lumbosacral radiculoplexus neuropathy
- Investigating an incidental finding of a paraprotein
- Diagnosis and treatment in inflammatory neuropathies
- Diagnosis of amyloid neuropathy
- POEMS neuropathy: optimising diagnosis and management
- CIDP: mimics and chameleons
- Neurology and the bone marrow